selinexor + pomalidomide + dexamethasone

Selinexor + pomalidomide + dexamethasone is an all-oral combination therapy used primarily in the treatment of relapsed or refractory multiple myeloma (RRMM). Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) that targets exportin 1 (XPO1), leading to nuclear retention and activation of tumor suppressor proteins, inhibition of NF-kB signaling, and reduction in c-MYC levels. Pomalidomide is an immunomodulatory agent that enhances T-cell and natural killer cell-mediated cytotoxicity and inhibits angiogenesis. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and antineoplastic effects. The combination has demonstrated synergistic activity in preclinical models and clinical trials, showing efficacy even in patients refractory to prior therapies including lenalidomide, bortezomib, or pomalidomide-based regimens. The recommended phase 2 dose for selinexor in this combination is typically 40–60 mg once weekly with standard doses of pomalidomide (4 mg daily on days 1–21 per cycle) and dexamethasone (40 mg weekly)[3][4][5][7]. Common adverse events include neutropenia, anemia, thrombocytopenia, fatigue, nausea, and diarrhea[5][7].

Other names

selinexor + pomalidomide + dexamethasoneSPd regimenXPd regimen